ID   FM6
AC   CVCL_C581
SY   FM-6; FM 6
DR   cancercelllines; CVCL_C581
DR   Cosmic; 808554
DR   Cosmic; 874437
DR   Cosmic; 972278
DR   Cosmic; 1047670
DR   Cosmic; 2163772
DR   ECACC; 13012409
DR   ESTDAB; ESTDAB-019
DR   GEO; GSM156021
DR   Progenetix; CVCL_C581
DR   Wikidata; Q54835054
RX   PubMed=7656272;
RX   PubMed=8968104;
RX   PubMed=9288767;
RX   PubMed=9688544;
RX   PubMed=15592718;
RX   PubMed=17260012;
RX   PubMed=23851445;
RX   PubMed=25728708;
CC   HLA typing: A*01,02; B*07,08 (PubMed=7656272).
CC   HLA typing: A*01:01,02:01; B*07:02,08:01; C*07:01:01,07:02; DPB1*04:01,01:01:01; DQB1*06:02,02:01; DRB1*03:01:01,15:01 (PubMed=15592718).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=17260012; PubMed=25728708).
CC   Omics: Array-based CGH.
CC   Derived from site: Metastatic; Not specified.
ST   Source(s): ECACC=13012409; ESTDAB=ESTDAB-019
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 11,12
ST   D3S1358: 14
ST   D5S818: 9,13
ST   D7S820: 9,10
ST   FGA: 23,24
ST   TH01: 9,9.3
ST   TPOX: 11,12
ST   vWA: 15,18
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 02-05-24; Version: 24
//
RX   PubMed=7656272; DOI=10.1007/BF01527402;
RA   Kirkin A.F., Petersen T.R., Olsen A.C., Li L., thor Straten P.,
RA   Zeuthen J.;
RT   "Generation of human-melanoma-specific T lymphocyte clones defining
RT   novel cytolytic targets with panels of newly established melanoma cell
RT   lines.";
RL   Cancer Immunol. Immunother. 41:71-81(1995).
//
RX   PubMed=8968104;
RA   Bartkova J., Lukas J., Guldberg P., Alsner J., Kirkin A.F.,
RA   Zeuthen J., Bartek J.;
RT   "The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently
RT   altered in melanoma pathogenesis.";
RL   Cancer Res. 56:5475-5483(1996).
//
RX   PubMed=9288767;
RA   Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A.F.,
RA   Zeuthen J.;
RT   "Disruption of the MMAC1/PTEN gene by deletion or mutation is a
RT   frequent event in malignant melanoma.";
RL   Cancer Res. 57:3660-3663(1997).
//
RX   PubMed=9688544; DOI=10.1016/S0014-5793(98)00603-6;
RA   Dzhandzhugazyan K.N., Kirkin A.F., thor Straten P., Zeuthen J.;
RT   "Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated
RT   human melanomas.";
RL   FEBS Lett. 430:227-230(1998).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=25728708; DOI=10.1111/pcmr.12364;
RA   Vogel C.J., Smit M.A., Maddalo G., Possik P.A., Sparidans R.W.,
RA   van der Burg S.H., Verdegaal E.M.E., Heck A.J.R., Samatar A.A.,
RA   Beijnen J.H., Altelaar A.F.M., Peeper D.S.;
RT   "Cooperative induction of apoptosis in NRAS mutant melanoma by
RT   inhibition of MEK and ROCK.";
RL   Pigment Cell Melanoma Res. 28:307-317(2015).
//